Denali Therapeutics Inc. (DNLI)
Health Care ยท Biological Products, (No Diagnostic Substances)
Denali Therapeutics Inc. (DNLI) is listed on Nasdaq, where its shares have traded since December 8, 2017. SentiSense covers Denali Therapeutics Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Ryan Watts is its chief executive officer. The company reports 507 employees, and its corporate website is www.denalitherapeutics.com.
About Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Latest reported results
Denali Therapeutics reported revenue of $17.8 million for Q3 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 284 institutions reported holding DNLI, with 156.2 million shares worth $4.0 billion in aggregate. The largest reported holders were T. Rowe Price, BlackRock and Vanguard. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on DNLI
- DNLI sentiment: whether news and social coverage of Denali Therapeutics Inc. leans bullish or bearish, and the stories driving it.
- DNLI ownership: all 284 reporting institutions, plus insider and congressional trades.
- DNLI financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Denali Therapeutics Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Denali Therapeutics Inc. do?
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases.
What sector is DNLI in?
SentiSense classifies Denali Therapeutics Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does DNLI stock trade?
Denali Therapeutics Inc. (DNLI) is listed on Nasdaq, where its shares have traded since December 8, 2017.
Who is the CEO of Denali Therapeutics Inc.?
Ryan Watts is the chief executive officer of Denali Therapeutics Inc..